Neuren Pharmaceuticals Limited · ASX:NEU

Neuren Pharmaceuticals — J.P. Morgan Healthcare Conference 2025

14 slides from Neuren Pharmaceuticals's conference presentation, Jan 16, 2025

  1. Slide 1: J.P. Morgan Healthcare Conference 2025

    For personal use only J.P.Morgan Healthcare Conference 2025 16 Jan 2025 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES Pa g e□1

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward looking statements that involve For personal use only risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expe

  3. Slide 3: Seeking a ground-breaking impact on neurodevelopmental disorders

    Seeking a ground-breaking impact on neurodevelopmental disorders Rett Fragile X Phelan-McDermid Angelman Pitt Hopkins Prader-Willi For personal use only MECP2 FMR1 SHANK3 UBE3A TCF4 15q11-q13 Neuren’s drugs Impaired communication between neurons, abnormal target the critical role of IGF-1 formation/

  4. Slide 4: Commercial and late-stage pipeline

    Commercial and late-stage pipeline Commercial Indication Compound Geography Preclinical Phase 2 Phase 3 Registration rights For personal use only US, Canada Trofinetide Rett RoW NNZ-2591 World Trofinetide World Fragile X NNZ-2591 World Positive Phase 2 Phelan-McDermid NNZ-2591 World results Positive

  5. Slide 5: Large potential upside supported by robust financial foundation

    Large potential upside supported by robust financial foundation For personal use only Maximise value of NNZ-2591 as a multiple indication platform  Positive Phase 2 results for Phelan-McDermid syndrome  Positive Phase 2 results for Pitt Hopkins syndrome Value  Positive Phase 2 results for Angelma

  6. Slide 6: DAYBUE is a highly successful rare disease launch in the US

    DAYBUE is a highly successful rare disease launch in the US US Net Sales (US$m) Significant further growth potential in the US1: CY24 DAYBUE US$340-350m For personal use only • Diagnosed population expanding towards CY23 DAYBUE US$177m prevalence of 6,000-9,000 98 91 • Currently 5,500–5,800 diagnose

  7. Slide 7: Long term growth opportunity through global expansion

    Long term growth opportunity through global expansion Canada For personal use only 600 - 900 Rett patients1 Approved in Oct 2024 Europe First sales in Q3 2025 9,000 - 12,000 Rett patients1 US MAA filed with potential approval Japan Q1 2026 6,000 - 9,000 Rett patients1 1,000 - 2,000 Rett patients1 In

  8. Slide 8: Economics to Neuren from Acadia partnership

    Economics to Neuren from Acadia partnership North America Outside North America For personal use only  US$10m upfront in 2018  US$100m upfront in 2023  US$10m in 2022 following acceptance of NDA for review US$35m following 1st commercial sale in Europe  US$40m in 2023 following 1st commercial sa

  9. Slide 9: Growing sustainable income to Neuren from DAYBUE

    Growing sustainable income to Neuren from DAYBUE Neuren Income A$ million For personal use only 238 216 - 218 76 146 11 76 6 18 56 59 16 54 13 13 vs 27 12 Q1 2024 Q2 2024 Q3 2024E~ Q4 2024E* CY2024E^ CY2023 Royalty Royalty estimate range Milestone Interest Income PRV Up-front ~ Based on 10% of DAYBU

  10. Slide 10: Multiple indications opportunity for NNZ-2591

    Multiple indications opportunity for NNZ-2591 • Positive results in PMS, PTHS and AS syndrome Phase 2 trials For personal use only • Most advanced clinical program in PMS Prader-Willi and PTHS, oral therapy competitive in AS syndrome • Positive End of Phase 2 meeting with FDA for PMS - alignment on

  11. Slide 11: Phase 2 trial results validating multi-indication platform

    Phase 2 trial results validating multi-indication platform Phelan-McDermid syndrome Pitt Hopkins syndrome (PTHS) Angelman syndrome (PMS) N=11, 13 weeks (AS) N=18, 13 weeks N=13, 13 weeks For personal use only Safe and well tolerated, with no meaningful trends in laboratory values or other safety par

  12. Slide 12: Significant market opportunity

    Significant market opportunity No approved treatment for PMS, PTHS or AS For personal use only Competitive Position Estimated Prevalence Potential Patients in the US4 Phelan-McDermid Most advanced clinical 1/8,000 to 1/15,000 males and 17,000 - 32,000 syndrome (PMS) program females1 Pitt Hopkins Mos

  13. Slide 13: Key milestones

    Key milestones Milestones Achieved in 2024 2025 Milestones For personal use only  9 months to date CY2024 DAYBUE net sales  Submission by Acadia of EU marketing application for trofinetide of ~US$252m in the US, generated A$38m • CY2024E Neuren total income of A$216 – 218m1 royalties to Neuren and

  14. Slide 14: Contact

    For personal use only CONTACT [email protected] Authorised by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 14

Neuren Pharmaceuticals — J.P. Morgan Healthcare Conference 2025 on 6ix